Susquehanna International Group
TARS icon

Susquehanna International Group’s Tarsus Pharmaceuticals TARS Stock Holding History

Susquehanna International Group’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.43M Buy
34,600
+5,100
+17% +$356K ﹤0.01% 5725
2025
Q4 		$2.42M Buy
29,500
+11,800
+67% +$881K ﹤0.01% 5249
2025
Q3 		$1.05M Buy
+17,700
New +$871K ﹤0.01% 7244
2025
Q2 		– Sell
-5,300
Closed -$272K – 13699
2025
Q1 		$272K Sell
5,300
-13,100
-71% -$648K ﹤0.01% 10264
2024
Q4 		$1.02M Sell
18,400
-9,200
-33% -$418K ﹤0.01% 6895
2024
Q3 		$908K Sell
27,600
-3,400
-11% -$95.6K ﹤0.01% 7005
2024
Q2 		$843K Buy
31,000
+5,700
+23% +$192K ﹤0.01% 6992
2024
Q1 		$920K Buy
+25,300
New +$744K ﹤0.01% 7105
2023
Q4 		– Sell
-19,100
Closed -$339K – 13274
2023
Q3 		$339K Buy
19,100
+3,600
+23% +$63.7K ﹤0.01% 9094
2023
Q2 		$280K Buy
+15,500
New +$246K ﹤0.01% 9579
2022
Q4 		– Sell
-26,300
Closed -$450K – 13639
2022
Q3 		$450K Sell
26,300
-1,100
-4% -$17.5K ﹤0.01% 8770
2022
Q2 		$400K Buy
+27,400
New +$411K ﹤0.01% 8811

Other funds holding TARS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Susquehanna International Group's TARS Position: Q1 2026 in Review

Susquehanna International Group increased its Tarsus Pharmaceuticals (TARS) stake by 77% in Q1 2026, buying an estimated $504K and bringing the position to 16,635 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #7476.

Susquehanna International Group first reported a position in TARS in Q3 2022 and has held it in 10 quarters since. The position peaked at $3.55M in Q4 2024. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

  • Susquehanna International Group held 16,635 shares of Tarsus Pharmaceuticals worth $1.17M as of Q1 2026.
  • Susquehanna International Group bought 7,213 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $504K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7476 holding.
  • Susquehanna International Group first reported a position in Tarsus Pharmaceuticals in Q3 2022 and has held it in 10 quarters since.
  • Susquehanna International Group's Tarsus Pharmaceuticals position peaked at $3.55M in Q4 2024.
  • 253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.